A more detailed knowledge on the molecular mechanisms by which VPS35 promotes α-synuclein clearance could serve to clarify the role of VPS35-retromer protein in PD and to identify alternative and efficient new potential therapeutic targets downstream to VPS35 action. This evidence concerns the gene VPS35 and Parkinson disease.